Labcorp Agrees to Buy BioReference Assets for $872M

Labcorp and OPKO Health entered an agreement announced Thursday, October 15, 2026, for Labcorp to acquire select BioReference Health laboratory assets. Labcorp will pay $722 million in cash at closing, with up to an additional $150 million tied to 4Kscore Test revenue, for a total potential value of about $872 million. The purchase covers clinical testing, women's health, urology and corrections testing businesses, more than 80 patient service centers, and the FDA-approved 4Kscore Test, used to assess the likelihood of aggressive prostate cancer before biopsy. That test generated $27.1 million in revenue in 2025. Labcorp expects the acquired businesses to generate about $250 million in revenue in the first year after closing. The transaction remains subject to regulatory clearance and other closing conditions; no expected closing date was given. OPKO stock closed Wednesday at $1.37, up 3.79%, and was up 21.90% to $1.67 in premarket trading, per RTTNews. Contested: none found.